Compugen Ltd (NASDAQ: CGEN)

Compugen Ltd was incorporated on February 10 1993 as an Israeli corporation and continues to operate under the Companies Law.

The company describes itself as a clinical stage therapeutic discovery and development firm that focuses on cancer immunotherapy.

Its core activity revolves around the Unigen platform an AI ML powered computational system that predicts novel drug targets and guides experimental validation.

Through Unigen Compugen has identified several immune checkpoint targets including PVRIG TIGIT and IL 18 binding protein which have been translated into antibody candidates.

The most advanced programs are COM701 an anti PVRIG antibody COM902 an anti TIGIT antibody rilvegostomig a PD 1 TIGIT bispecific antibody developed with AstraZeneca and GS 0321 formerly known as COM503 an anti IL 18 binding protein antibody licensed to Gilead.

All of these candidates are currently being evaluated in clinical trials either sponsored by Compugen or by its partners.

The company maintains its principal offices in Holon Israel and a wholly owned US subsidiary in San Francisco California that supports administrative and partnership functions.

Compugen generates revenue principally through licensing and collaboration agreements with pharmaceutical and biotechnology partners.

These agreements typically include an upfront license fee milestone payments tied to development regulatory or commercial events and royalties on net sales of any resulting products.

For example the Gilead license for GS 0321 provided an upfront payment of sixty million dollars and a subsequent milestone payment of thirty million dollars upon IND clearance with additional potential milestones that could reach nearly seven hundred fifty eight million dollars.

The AstraZeneca agreement for rilvegostomig delivered an initial ten million dollar upfront payment and multiple milestone payments that have already been triggered by clinical trial progress.

Further amendments to the AstraZeneca deal have included additional cash considerations and adjustments to royalty structures while preserving the company’s eligibility for future milestones.

Compugen also receives research funding from collaborators to support specific clinical trials such as the Phase 1 study of GS 0321 conducted with Gilead supplied zimberelimab.

The Bristol Myers Squibb collaboration provided early stage investments and supported combination studies of COM701 with nivolumab and BMS 986207 without generating direct product revenue.

Overall the company has not yet recorded any product sales revenue as all of its therapeutic candidates remain in pre commercial development stages.

Capital expenditures have been modest with amounts of zero point three million dollars in 2025 zero point one million in 2024 and zero point two million in 2023 reflecting a limited need for manufacturing infrastructure.

Compugen does not report separate operating segments because it manages its activities as a single unit dedicated to drug discovery and development.

Compugen competes in the immuno oncology sector where large pharmaceutical corporations and numerous biotechnology firms pursue checkpoint inhibitor and immune modulating therapies.

Direct competitors include well known companies such as Bristol Myers Squibb Merck Roche AstraZeneca and Novartis which have approved PD 1 CTLA 4 LAG 3 and TIGIT based drugs.

In addition many smaller biotech entities focus on novel immune targets and on combining modalities such as bispecific antibodies T cell engagers and cytokine based approaches.

The global market for immune checkpoint inhibitors was estimated at approximately fifty eight point five three billion dollars in 2025 and is projected to reach about two hundred twenty nine point six billion dollars by 2034 reflecting a compound annual growth rate of sixteen point four percent.

Compugen seeks to distinguish itself by leveraging its Unigen platform which integrates artificial intelligence and machine learning with deep biological insight to predict targets that may be missed by conventional methods.

This approach has already yielded several clinically advanced candidates including PVRIG TIGIT and IL 18 pathway modulators demonstrating the platform’s ability to move from in silico prediction to laboratory validation and early clinical testing.

The company’s intellectual property portfolio includes a substantial number of issued patents and pending applications covering its discovered targets and related antibody formulations providing a legal barrier to entry.

Together these elements give Compugen a competitive niche that emphasizes scientific innovation and capital efficient partnership models.

Compugen’s customers and collaborators are primarily pharmaceutical and biotechnology companies that seek to license its novel targets or to co develop therapeutic candidates.

The filing specifically names Gilead Sciences AstraZeneca and Bristol Myers Squibb as partners with whom the company has executed license and collaboration agreements.

Through the Gilead agreement Compugen is responsible for conducting the Phase 1 trial of GS 0321 while Gilead supplies the companion anti PD 1 antibody zimberelimab and holds worldwide commercialization rights.

The AstraZeneca arrangement grants the partner exclusive rights to use Compugen’s TIGIT targeting molecules to create bispecific and multi specific antibodies such as rilvegostomig with AstraZeneca bearing all research development and commercial costs.

The Bristol Myers Squibb collaboration has supported combination studies of COM701 with nivolumab and BMS 986207 and has included equity investments that strengthened the company’s balance sheet.

Although Compugen does not sell products directly to patients the ultimate beneficiaries of its pipeline are individuals receiving investigational therapies in clinical trials conducted by the company or its partners.

Thus the company’s customer base consists of a limited set of strategic industry allies whose success in advancing the candidates may eventually translate into broader patient access.